Fact checked byGina Brockenbrough, MA

Read more

August 18, 2024
1 min read
Save

Smith & Nephew reports increased revenue in second-quarter 2024 financial results

Fact checked byGina Brockenbrough, MA
You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Key takeaways:

  • Smith & Nephew reported revenue growth in its second-quarter 2024 financial results
  • The company reported $1.441 billion in revenue for the second quarter of 2024.

Smith & Nephew announced increased revenue across several businesses in its second quarter of 2024 financial results, according to a company press release.

“Today’s results are further evidence of the good progress we are making transforming Smith & Nephew into a higher growth and more profitable business,” Deepak Nath, CEO of Smith & Nephew, said in the release. “Across the majority of orthopedics, which was our underperforming business unit, we are now consistently achieving growth rates well above historical levels.”

Person pointing at growth chart
Smith & Nephew reported revenue growth in its second-quarter 2024 financial results. Image: Adobe Stock

Smith & Nephew reported $1.441 billion in revenue for the second quarter, a 5.6% increase from the prior year period. The company also reported revenue growth in its orthopedics (5.8%), sports medicine and ear, nose and throat (7.6%), and advanced wound management (3.3%) businesses compared with the second quarter of 2023.

“Our investment in innovation continues to deliver. In the first half of 2024, we delivered several major launches and product enhancements,” Nath said. “For example, we continued to expand our CORI surgical system, which is now a recognized leader in robotics-assisted surgery. We also achieved full commercial launch of our AETOS shoulder system, addressing one of the fastest growing segments in orthopedics and U.S. regulatory approval for our new Catalystem hip system.”